Revvity, Inc. RVTY SPXR3KPHARMA
Company Overview
Revvity, Inc. provides health sciences solutions, technologies, and services. The company offers instruments, reagents, software, subscriptions, detection and imaging technologies, extended warranties, training and services; and instruments, reagents, assay platforms and software products for early detection of common and rare conditions, such as pregnancy and early childhood, as well as infectious disease testing in the diagnostics market. Its products are used for testing and screening genetic abnormalities, disorders, and diseases, including down syndrome, hypothyroidism, muscular dystrophy, infertility, and various metabolic conditions. The company also develops technologies that enable and support genomic workflows using protein coupled receptor and next-generation DNA sequencing for oncology, immunodiagnostics, and drug discovery. It serves pharmaceutical and biotechnology companies, laboratories, academic and research institutions, public health authorities, private healthcare organizations, doctors, and government agencies under the AutoDELFIA, chemagic, Chitas, CNGnome, DELFIA, DELFIA Xpress, EONIS, EUROArray , EUROIMMUN, EUROLabWorkstation, EUROLINE, EUROPattern, Evolution Evoya, GSP, Haoyuan, IDS Immunodiagnosticsystems, IDS-i10, IDS-i10T, IDS-i20, IDS-iSYS, iLab, iQ, LifeCycle, LimsLink, Migele, NeoBase, NeoLSD, NEXTFLEX, Panthera Puncher, PreNAT II, Prime, RONIA, SimplicityChrom, Specimen Gate, Superflex, Symbio, T-SPOT, Vanadis, ViaCord, VICTOR2, and WholePanel brand names, as well as under the Accell, AlphaLISA, AlphaPlex, AlphaScreen, Alpha SureFire, AssayMate, BIOCHIPs, BioLegend, Bioo Scientific, BioQule, Brilliant Violet, Ce3D, CellCarrier, Cellaca, Celigo, Cellometer, cell::explorer, Cell-Vive, Chalice, ChemDraw, CHOSOURCE, Dharmacon, and DharmaFECT brand names. The company was formerly known as PerkinElmer, Inc. and changed its name to Revvity, Inc. in April 2023. Revvity, Inc. was founded in 1937 and is headquartered in Waltham, Massachusetts.
Why Investors Should Care
Operating margin of 17.1% supports profitability.
Generates positive free cash flow, funding growth and shareholder returns internally.
Recent Developments
- Dec 2025 Revenue of $2.86B (+3.7% YoY); net profit $241.20M.
- Trailing 12 Months Year-on-year growth — revenue +1.3%, earnings +1.2%.
- 5-Year Trend Long-term compounding — revenue CAGR 3.2%, profit CAGR 3.9%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | 3.24% |
| 1 Year: | 1.30% |
Compounded Profit Growth
| 5 Years: | 3.87% |
| 1 Year: | 1.20% |
Stock Price Performance
| 1 Year: | +73.53% |
| 6 Months: | +80.68% |
| 3 Months: | +42.45% |
| 1 Month: | +10.73% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMAAbove
- Price vs 200-DMAAbove
- RSI (14)64.07 · Neutral
P/E of 75.65 is above the sector median of 25.61 — pricier than peers.
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- Generates positive free cash flow.
- In a confirmed uptrend (50-DMA above 200-DMA).
CONS
- Trading at a high P/E of 75.7.
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | RVTY Revvity, Inc. SPXR3KPHARMA | 157.36 | 75.65 | $17.56B | 0.19% | 3.29% | 3.21% | 3.24% | 3.87% |
| 2 | LLY Eli Lilly and Company SPXR3KPHARMA | 1,306.69 | 43.95 | $1.16T | 0.60% | - | 102.29% | 7.20% | 11.41% |
| 3 | JNJ Johnson & Johnson SPXR3KPHARMA | 267.61 | 31.05 | $644.91B | 1.98% | 14.88% | 25.74% | 2.43% | 4.76% |
| 4 | ABBV AbbVie Inc. SPXR3KPHARMA | 285.19 | 80.56 | $503.96B | 2.54% | 10.47% | -129.24% | 1.75% | -29.06% |
| 5 | UNH UnitedHealth Group Incorporated SPXR3KPHARMA | 424.98 | 27.29 | $381.46B | 2.47% | 9.74% | 14.15% | 10.40% | 5.43% |
| 6 | MRK Merck & Co., Inc. SPXR3KPHARMA | 147.24 | 117.79 | $363.27B | 2.31% | - | 6.96% | 5.64% | 10.01% |
| 7 | NVS Novartis AG PHARMA | 156.27 | 23.61 | $297.02B | 3.36% | 21.09% | 30.35% | 9.25% | 26.22% |
| 8 | AZN AstraZeneca PLC NDXPHARMA | 172.57 | 25.80 | $267.64B | 2.00% | 15.97% | 21.96% | 9.82% | 45.96% |
| 9 | TMO Thermo Fisher Scientific Inc. SPXR3KPHARMA | 676.54 | 36.45 | $250.15B | 0.29% | 8.14% | 13.51% | 8.81% | 12.95% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Oct 2015 | Jan 2016 | Apr 2016 | Jul 2016 | Oct 2016 | Jan 2017 | Apr 2017 | Jul 2017 | Oct 2017 | Dec 2017 | Apr 2018 | Jul 2018 | Sep 2018 | Dec 2018 | Mar 2019 | Jun 2019 | Sep 2019 | Dec 2019 | Apr 2020 | Jul 2020 | Oct 2020 | Jan 2021 | Apr 2021 | Jul 2021 | Oct 2021 | Jan 2022 | Apr 2022 | Jul 2022 | Oct 2022 | Jan 2023 | Apr 2023 | Jul 2023 | Oct 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Apr 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | 546.96M | 554.27M | - | 643.97M | 703.36M | 674.31M | - | 648.74M | 722.52M | 706.92M | - | 652.40M | 811.72M | 964.02M | - | 1.31B | 1.23B | 861.32M | - | 963.16M | 895.64M | 711.80M | - | 674.87M | 709.07M | 670.74M | 649.92M | 691.68M | 684.05M | 664.76M | 720.28M | 698.95M | 711.12M |
| Gross Profit | 239.37M | 267.73M | 235.09M | 253.55M | 248.55M | 276.16M | 239.76M | 257.60M | 268.97M | 307.43M | 292.22M | 340.14M | 332.33M | 376.25M | 307.81M | 347.79M | 342.27M | 398.18M | 308.02M | 447.34M | 527.45M | 827.07M | 693.19M | 574.14M | 522.86M | 643.80M | 594.74M | 551.72M | 407.04M | 436.33M | - | - | - | - | - | - | - | - | - | - |
| Operating Income | 67.39M | 77.22M | 60.58M | 66.27M | 75.78M | 80.44M | 49.81M | 74.18M | 78.04M | 93.58M | 39.94M | 88.06M | 80.20M | 115.68M | 53.33M | 91.73M | 78.66M | 138.25M | 44.68M | 175.64M | 248.01M | 510.25M | 455.01M | 308.00M | 195.55M | 299.89M | 261.96M | 232.49M | 110.78M | 137.47M | 76.12M | 78.06M | 69.23M | 44.12M | 85.72M | 98.15M | 72.23M | 90.76M | 81.90M | 75.89M |
| Net Income | 54.86M | 68.25M | 47.47M | 63.86M | 58.13M | 64.85M | 38.60M | 204.07M | 91.08M | -41.12M | 26.02M | 64.06M | 76.55M | 71.29M | 35.41M | 69.09M | 58.56M | 64.50M | 33.66M | 137.16M | 176.70M | 380.36M | 379.31M | 245.93M | 127.74M | 190.18M | 176.96M | 179.21M | 85.35M | 127.66M | 569.48M | 35.56M | 9.50M | 26.01M | 55.36M | 94.37M | 42.24M | 53.95M | 46.65M | 40.72M |
| Diluted EPS | 0.48 | 0.61 | 0.43 | 0.58 | 0.53 | 0.59 | 0.35 | 1.84 | 0.82 | -0.37 | 0.23 | 0.57 | 0.69 | 0.64 | 0.32 | 0.62 | 0.52 | 0.58 | 0.30 | 1.23 | 1.57 | 3.38 | 3.37 | 2.19 | 1.11 | 1.50 | 1.40 | 1.42 | 0.67 | 1.01 | 4.50 | 0.28 | 0.08 | 0.21 | 0.45 | 0.77 | 0.35 | 0.46 | 0.40 | 0.36 |
| R&D Expense | 31.09M | - | 29.97M | 31.87M | 29.51M | - | 33.29M | 33.56M | 34.88M | - | 45.98M | 47.20M | 48.85M | - | 47.98M | 48.34M | 45.38M | - | 48.91M | 49.52M | 50.13M | - | 60.22M | 65.82M | 49.42M | - | 57.52M | 56.04M | 53.52M | - | 56.69M | 57.25M | 53.04M | 50.36M | 48.13M | 49.14M | 53.60M | 53.27M | 50.80M | 57.89M |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2008 | Jan 2010 | Jan 2011 | Jan 2012 | Dec 2012 | Dec 2013 | Dec 2014 | Jan 2016 | Jan 2017 | Dec 2017 | Dec 2018 | Dec 2019 | Jan 2021 | Jan 2022 | Jan 2023 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 1.66B | 1.55B | 1.70B | 1.92B | 2.12B | 2.16B | 2.24B | 2.10B | 2.12B | 2.26B | 2.78B | 2.88B | 2.66B | 3.83B | 3.31B | 2.75B | 2.76B | 2.86B |
| Gross Profit | - | - | 761.23M | 847.80M | 963.21M | 976.14M | 1.00B | 964.23M | 1.01B | 1.07B | 1.34B | 1.40B | 2.11B | 2.43B | 1.99B | - | - | - |
| Operating Income | 147.63M | 115.95M | 157.57M | 91.13M | 103.12M | 227.79M | 165.01M | 250.93M | 294.58M | 295.62M | 323.88M | 361.97M | 867.27M | 1.26B | 742.70M | 300.56M | 346.74M | 356.63M |
| Net Income | 126.41M | 82.08M | 390.98M | 7.66M | 69.94M | 167.21M | 157.78M | 212.43M | 234.30M | 292.63M | 237.93M | 227.56M | 727.89M | 943.16M | 569.18M | 693.09M | 270.38M | 241.20M |
| Diluted EPS | 1.07 | 0.70 | 3.31 | 0.07 | 0.61 | 1.47 | 1.39 | 1.87 | 2.12 | 2.64 | 2.13 | 2.04 | 6.49 | 8.08 | 4.50 | 5.55 | 2.20 | 2.07 |
| R&D Expense | 93.03M | 90.49M | 94.81M | 115.82M | 131.84M | 132.40M | 108.06M | 112.54M | 124.18M | 139.46M | 194.00M | 189.34M | 146.44M | 200.34M | 221.62M | 216.58M | 196.84M | 215.84M |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2007 | Dec 2008 | Jan 2010 | Jan 2011 | Jan 2012 | Dec 2012 | Dec 2013 | Dec 2014 | Jan 2016 | Jan 2017 | Dec 2017 | Dec 2018 | Dec 2019 | Jan 2021 | Jan 2022 | Jan 2023 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Assets | - | - | 3.06B | 3.21B | 3.86B | 3.90B | 3.95B | 4.13B | 4.17B | 4.28B | 6.09B | 5.98B | 6.54B | 7.96B | 15.00B | 14.13B | 13.56B | 12.39B | 12.17B |
| Total Equity | 1.58B | 1.57B | 1.63B | 1.93B | 1.84B | 1.94B | 1.99B | 2.04B | 2.11B | 2.15B | 2.50B | 2.58B | 2.81B | 3.74B | 7.14B | 7.38B | 7.87B | 7.67B | 7.25B |
| Cash & Equivalents | 203.35M | 179.11M | 179.71M | 420.09M | 142.34M | 173.24M | 174.82M | 174.82M | 237.93M | 359.26M | 202.13M | 163.11M | 191.88M | 387.05M | 603.32M | 454.36M | 913.16M | 1.16B | 919.86M |
| Long Term Debt | - | - | 558.20M | 424.00M | 944.91M | 938.82M | 932.10M | 1.05B | 1.01B | 1.05B | 1.79B | 1.88B | 2.06B | 1.61B | 4.98B | 3.92B | 3.18B | 3.15B | 2.63B |
| Total Liabilities | - | - | 1.43B | 1.28B | 2.01B | 1.96B | 1.95B | 2.09B | 2.06B | 2.12B | 3.59B | 3.39B | 3.72B | 4.22B | 7.86B | 6.75B | 5.69B | 4.73B | 4.92B |
| Current Liabilities | - | - | 497.20M | 515.20M | 598.68M | 581.10M | 602.80M | 597.31M | 561.49M | 603.36M | 950.90M | 771.63M | 762.83M | 1.65B | 1.21B | 1.54B | 1.45B | 653.10M | 1.33B |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2008 | Jan 2010 | Jan 2011 | Jan 2012 | Dec 2012 | Dec 2013 | Dec 2014 | Jan 2016 | Jan 2017 | Dec 2017 | Dec 2018 | Dec 2019 | Jan 2021 | Jan 2022 | Jan 2023 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | 217.84M | 148.72M | 164.25M | 224.87M | 152.17M | 158.59M | 281.60M | 287.10M | 350.62M | 288.45M | 311.04M | 363.47M | 892.18M | 1.41B | 679.81M | 91.27M | 628.30M | 582.93M |
| Investing Cash Flow | -135.68M | -153.87M | 295.15M | -909.86M | -80.31M | -1.21M | -295.90M | -100.86M | -83.88M | -1.27B | -159.86M | -487.57M | -504.50M | -4.11B | -132.85M | 1.31B | 776.16M | -17.35M |
| Financing Cash Flow | -101.08M | 2.41M | -218.37M | 397.20M | -44.16M | -154.16M | 30.93M | -107.14M | -115.01M | 782.24M | -179.23M | -150.13M | -202.87M | 2.94B | -661.80M | -947.12M | -1.13B | -857.52M |
| Capital Expenditure | -35.27M | -25.52M | -33.65M | -30.59M | -42.40M | -38.98M | -27.15M | -28.22M | -31.70M | -39.09M | -93.25M | -76.33M | -63.63M | -86.02M | -85.63M | -81.37M | -86.65M | -73.52M |
| Free Cash Flow | 182.57M | 123.21M | 130.61M | 194.28M | 109.77M | 119.61M | 254.44M | 258.88M | 318.91M | 249.36M | 217.78M | 287.14M | 828.54M | 1.32B | 594.18M | 9.90M | 541.65M | 509.41M |
| Share Buybacks | 75.51M | 14.62M | 72.77M | 110.00M | 2.10M | 127.40M | 65.53M | 76.44M | 151.80M | 3.83M | 57.45M | 6.31M | 6.94M | 73.07M | 80.64M | 388.88M | 369.58M | 820.82M |
Ratios (Annual)
Figures in %.
| Metric | Dec 2008 | Jan 2010 | Jan 2011 | Jan 2012 | Dec 2012 | Dec 2013 | Dec 2014 | Jan 2016 | Jan 2017 | Dec 2017 | Dec 2018 | Dec 2019 | Jan 2021 | Jan 2022 | Jan 2023 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin % | - | - | 44.7% | 44.2% | 45.5% | 45.2% | 44.9% | 45.8% | 47.9% | 47.6% | 48.3% | 48.4% | 79.2% | 63.6% | 60.1% | - | - | - |
| Operating Margin % | 8.9% | 7.5% | 9.2% | 4.7% | 4.9% | 10.6% | 7.4% | 11.9% | 13.9% | 13.1% | 11.7% | 12.6% | 32.6% | 32.9% | 22.4% | 10.9% | 12.6% | 12.5% |
| Net Margin % | 7.6% | 5.3% | 22.9% | 0.4% | 3.3% | 7.7% | 7.1% | 10.1% | 11.1% | 13.0% | 8.6% | 7.9% | 27.3% | 24.6% | 17.2% | 25.2% | 9.8% | 8.4% |
| ROE % | 8.1% | 5.0% | 20.3% | 0.4% | 3.6% | 8.4% | 7.7% | 10.1% | 10.9% | 11.7% | 9.2% | 8.1% | 19.5% | 13.2% | 7.7% | 8.8% | 3.5% | 3.3% |
| ROCE % | - | 4.5% | 5.8% | 2.8% | 3.1% | 6.8% | 4.7% | 7.0% | 8.0% | 5.8% | 6.2% | 6.3% | 13.7% | 9.1% | 5.9% | 2.5% | 3.0% | 3.3% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | T. Rowe Price Investment Management, Inc. | 16.37% | 18.26M | $2.82B |
| 2 | Jupiter Topco LLC | 7.74% | 8.64M | $1.33B |
| 3 | Edgepoint Investment Group Inc. | 7.66% | 8.54M | $1.32B |
| 4 | Blackrock Inc. | 6.86% | 7.66M | $1.18B |
| 5 | Vanguard Capital Management LLC | 6.54% | 7.30M | $1.13B |
| 6 | Price (T.Rowe) Associates Inc | 4.96% | 5.53M | $852.75M |
| 7 | Vanguard Portfolio Management LLC | 4.28% | 4.77M | $735.51M |
| 8 | State Street Corporation | 3.89% | 4.34M | $669.56M |
| 9 | Victory Capital Management Inc. | 3.27% | 3.65M | $562.13M |
| 10 | Dimensional Fund Advisors LP | 3.07% | 3.43M | $528.64M |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for RVTY
Revvity, Inc. (RVTY) stock price, news, quote and history - Yahoo Finance Singapore
<a href="https://news.google.com/rss/articles/CBMiUkFVX3lxTFB3OURxZ0c5NlA3V0FuSXNTOGJoYlhMcGVnY1g5NVIwWjljX2ZNSGg0NWZwSEVVR3RnMlV4c2hNUkRrNGl5N0hGMnJCaDNmY0FIQ0E?oc=5" target="_blank">Revvity, Inc. (RVTY) stock price, news, quote and histor…
Revvity: High PEG Ratio Leaves Limited Near-Term Upside (NYSE:RVTY) - Seeking Alpha
<a href="https://news.google.com/rss/articles/CBMimwFBVV95cUxPaDlYLV8tVU1HOEEzVDJQakpJOXdTUUlvTl8xOGFlNklvS2pTTW5NaWNHQmdKbjFRczg4U2NxQ0VqMzBIUGJWb0JVSF9qOF9Pd29KcTh6V2wzWVgtN0FVSU9KbjRMbXNLbVFxZHFubk9RMDZQalBhSEpDSTh1YmpqRVZaeTdqSjdId0JyZG…
Revvity, Inc. (RVTY) Stock Price, News, Quote & History - Yahoo! Finance Canada
<a href="https://news.google.com/rss/articles/CBMiUkFVX3lxTE41X3hOZW9vNVNwelRjVE45aU1FQU1fb2pRWnkxV2NsTXhxdkdFZExmRTFBN0lxS1YtRnRvZlZZMi1vRTNJYmRnTEROV3NCb2NZVUE?oc=5" target="_blank">Revvity, Inc. (RVTY) Stock Price, News, Quote & History<…
Revvity Launches Signals LabGistics to Coordinate Scientific Workflows - Zacks Investment Research
<a href="https://news.google.com/rss/articles/CBMihwJBVV95cUxOSlRud21rZWkzOXZKRHMycmpGS0tKNEhLTVB3a2tTMHkteUZ0aWN4c0tGMWE0YVl4c2N0QVZQQ0pTTjdkRHgzVG9XdUg5eXJ5V0taNlUyMDRmRUh4MEdPR01ydlFacGNpN0xZdnhRSWNEdDhQb1BVeXNvQXIwVGlJMjFHM05jdnVOenFhal…
Revvity: A Diagnostics Annuity Is Quietly Funding An AI Data Engine - Seeking Alpha
<a href="https://news.google.com/rss/articles/CBMiqAFBVV95cUxQZWFJYUVZZktsOUZMb1dCQjcyQ1pFN1hzMlI0bTFlRThLa21qZHpNODlCQnNSQ1B6bDRVVExWTS0wM1dOTFkyamJVZWE1QXEzdnRGTmVuTV9nYXpZZFpaQnkyZXBma1Z3TjNLcmVvM3ppbDBCTkw4Rmxwb3F4bnVaVWFhblMtcF9yMXMtOE…
RVTY Stock Price and Chart — NYSE:RVTY - TradingView
<a href="https://news.google.com/rss/articles/CBMiWkFVX3lxTE5OekM5YThwTHJoZ3lERkgwTUlpUnoxMlpYblZ5S0xvbEx6bFJDOV8yeXZUakhaODBYZEJxcDFhMkFROGUxRDhOaHFFcHpTdmhnUFg4ODJTaHhCZw?oc=5" target="_blank">RVTY Stock Price and Chart — NYSE:RVTY</a>&nb…
RVTY — Frequently Asked Questions
What is the current share price of Revvity, Inc. (RVTY)?
As of 2026-10-22 16:30 PDT, Revvity, Inc. (RVTY) trades at $157.36 on NYSE. Its 52-week range is $82.21 to $157.36.
What is the market capitalisation of RVTY?
Revvity, Inc. (RVTY) has a market capitalisation of $17.56B on NYSE.
What is the P/E ratio of RVTY?
RVTY trades at a trailing price-to-earnings (P/E) ratio of 75.65. The industry average P/E is 25.61. Its price-to-book (P/B) ratio is 2.21.
Does RVTY pay a dividend?
Revvity, Inc. (RVTY) currently offers a dividend yield of 0.19%.
What is the return on equity (ROE) of RVTY?
RVTY has a return on equity (ROE) of 3.21%. Its return on capital employed (ROCE) is 3.29%.
Is RVTY a good stock to buy?
This page provides a data-driven analysis of Revvity, Inc. (RVTY), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.